Portola Presents New Interim Data from Ongoing Phase 2a Study Cerdulatinib
09 Dec 2019 //
PR NEWSWIRE
Dermavant Announces 1st Patient Dosed in Phase 2a Clinical Trial of Cerdulatinib
03 Dec 2019 //
GLOBE NEWSWIRE
Portola Pharmaceuticals R&D Exec to Retire
24 Apr 2019 //
GLOBENEWSWIRE
Dermavant hires Todd Zavodnick as CEO
15 Nov 2018 //
FIERCE BIOTECH

Market Place
Sourcing Support